KINNATE BIOPHARMA INC (KNTE) Stock News
NASDAQ:KNTE - Nasdaq - US49705R1059 - Common Stock - Currency: USD
KNTE Latest News, Press Relases and Analysis
XOMA Corporation Announces Closing of Tender Offer
Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right
Mentions: XOMA
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.
/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kinnate Biopharma Inc. (NASDAQ: KNTE) and its board of directors...
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio
Mentions: XOMA
Kinnate Biopharma Inc. vende su inhibidor Pan-RAF en fase de investigación, exarafenib, a Pierre Fabre Laboratories
Kinnate ha firmado un Acuerdo de Compra de Activos ("APA", por sus siglas en inglés) con Pierre Fabre Laboratories por los derechos mundiales del exarafenib y...
Kinnate Biopharma Inc. verkauft seinen in der Entwicklung befindlichen Pan-RAF-Inhibitor, Exarafenib an Pierre Fabre Laboratories
Kinnate hat mit Pierre Fabre Laboratories ein Asset Purchase Agreement („APA", Vertrag über den Kauf von Vermögenswerten) über die weltweiten Rechte an...
Kinnate Biopharma sells rights of exarafenib to Pierre Fabre laboratories (NASDAQ:KNTE)
Kinnate Biopharma sells global rights to exarafenib and other assets to Pierre Fabre Laboratories, receiving up to $31M in consideration.
Kinnate Biopharma Inc. vend son inhibiteur pan-RAF expérimental, l'exarafenib, aux Laboratoires Pierre Fabre
Kinnate a conclu une Convention d'achat d'actifs (l« APA ») avec les Laboratoires Pierre Fabre pour les droits mondiaux sur l'exarafenib et d'autres actifs du...
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program...
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties. The sale of global rights is in furtherance of the Company’s previously announced exploration of strategic alternatives.
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA
/PRNewswire/ -- Ademi LLP is investigating Kinnate (Nasdaq: KNTE) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024.
Mentions: XOMA
Xoma to acquire Kinnate Biopharma (NASDAQ:XOMA)
XOMA Corporation (XOMA) announces plans to acquire Kinnate Biopharma (KNTE) for $2.3352-$2.5879 per share in cash, with a contingent value right. Read more here.
Mentions: XOMA
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage...
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio
Mentions: XOMA
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
SAN FRANCISCO and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced financial results for the third quarter of 2023 and recent corporate updates.